What is Amgen's stock-based comp?

Amgen (AMGN) reported stock-based comp of $75M in Q1 2026.

How has Amgen's stock-based comp changed year-over-year?

Amgen's stock-based comp decreased by 11.8% year-over-year, from $85M to $75M.

What is the long-term trend for Amgen's stock-based comp?

Over 4 years (2021 to 2025), Amgen's stock-based comp has grown at a 9.7% compound annual growth rate (CAGR), from $341M to $494M.

What does stock-based comp mean?

Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.

Amgen AMGN Stock-Based Comp

Stock-Based Comp at other companies

Eli LillyLLY

$161M+4.5%

PfizerPFE

$272M+60.0%

Regeneron PharmaceuticalsREGN

$257.4M+0.7%

Nektar TherapeuticsNKTR

$3.36M-13.9%

Oruka Therapeutics, Inc.ORKA

$6.97M+42.7%

Rigel PharmaceuticalsRIGL

$3.46M+4.0%

Other financials

Income statement

See full

Revenue$8.6B+5.8%

Gross profit$5.9B+13.4%

Operating income$2.7B+126%

Net income$1.8B+5.1%

EPS (diluted)$3.34+4.4%

Balance sheet

See full

Cash & equivalents$559.0M+10.0%

Total debt$57.3B-0.1%

Total equity$9.2B+48.1%

Total assets$92.5B+3.5%

Cash flow

See full

Operating cash flow$2.2B+57.4%

CapEx$712.0M+73.2%

Free cash flow$1.5B+50.7%

Valuation

See full

Market cap$193.39B+29.6%

Enterprise value$250.16B+22.1%

P/E24.8×+2.3×

P/S5.2×+0.9×

Profitability

See full

Gross margin68.3%+5.3pp

Operating margin28.4%+6.6pp

Net margin21%+3.6pp

FCF margin23.1%-8.9pp

Returns & leverage

See full

Return on equity101.3%-4.4pp

Debt / equity6.2×-3.0×

Current ratio1.3×+0.1×

Where this comes from

Reported directly by Amgen in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: Amgen’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Amgen's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Amgen's stock-based comp?: Amgen (AMGN) reported stock-based comp of $75M in Q1 2026.
How has Amgen's stock-based comp changed year-over-year?: Amgen's stock-based comp decreased by 11.8% year-over-year, from $85M to $75M.
What is the long-term trend for Amgen's stock-based comp?: Over 4 years (2021 to 2025), Amgen's stock-based comp has grown at a 9.7% compound annual growth rate (CAGR), from $341M to $494M.
What does stock-based comp mean?: Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.